Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SABS - SAB Biotherapeutics, Inc.

IEX Last Trade
4.19
1.545   36.874%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:22:36 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 3.82%

PREVIOUS CLOSE
CHG
CHG%
$2.64
1.55
58.41%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 10%
Liquidity 53%
Performance 5%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.83%
1 Month
35.31%
3 Months
51.29%
6 Months
39.45%
1 Year
-41.51%
2 Year
-40.58%
Key data
Stock price
$4.19
P/E Ratio 
-0.67
DAY RANGE
$2.64 - $4.16
EPS 
-$5.29
52 WEEK RANGE
$2.32 - $7.06
52 WEEK CHANGE
-$40.58
MARKET CAP 
27.134 M
YIELD 
N/A
SHARES OUTSTANDING 
9.229 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
0.08
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$89,196
AVERAGE 30 VOLUME 
$93,878
Company detail
CEO: Eddie J. Sullivan
Region: US
Website: sabbiotherapeutics.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Recent news